Related Experiment Video
Updated: Aug 22, 2026

Randomized Controlled Trial to Study the Acute Effects of Strength Exercise on Insulin Sensitivity in Obese Adults
Published on: December 1, 2023
Effect of high-dose vitamin E on insulin resistance and associated parameters in overweight subjects
Patrick J Manning1, Wayne H F Sutherland, Robert J Walker
1Department of Medical and Surgical Sciences, University of Otago, Private bag, Dunedin, New Zealand. patrickmanning@healthotago.co.nz
Objective:
Markers of oxidative stress and plasma alanine transferase (ALT) levels are increased and circulating antioxidant concentrations are reduced in individuals with insulin resistance. Vitamin E improves glycemic control in people with diabetes. We tested the hypothesis that vitamin E would decrease markers of oxidative stress and plasma ALT levels and improve insulin sensitivity in overweight individuals.
Research Design And Methods:
Eighty overweight individuals (BMI >27 kg/m(2)) were randomly allocated to receive either 800 IU vitamin E per day or a matching placebo for 3 months. The dose of vitamin E was increased to 1,200 IU per day for a further 3 months.
Results:
Plasma peroxides decreased by 27% at 3 months and by 29% at 6 months in the group that received vitamin E and were positively correlated with plasma vitamin E concentrations at the 6-month time point. At 3 months, fasting plasma glucose and insulin concentrations were significantly reduced and homeostasis model assessment increased. These changes were not apparent at 6 months. Plasma ALT concentrations declined significantly throughout the study period.
Conclusions:
In conclusion, these findings indicate that vitamin E improves oxidative stress and hepatocellular function. Although insulin resistance also improves, this effect appears transient.
Related Concept Videos
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Type II Diabetes II: Pathophysiology
Type II Diabetes I: Introduction
Drug Dosing: Obese Patients
Type I Diabetes II: Pathophysiology
Oral Hypoglycemic Agents: Biguanides and Glitazones
